Magellan Healthcare’s digital CBT programs demonstrate significant clinical efficacy

Magellan, in collaboration with NeuroFlow launched the Digital Emotional Wellbeing Suite in January 2022. It includes cognitive behavioural therapy (CBT) modules, FearFighter for anxiety, panic and phobia, and MoodCalmer for depression. Magellan has now released member outcomes showing that its CBT modules are consistent with published results demonstrating equivalent outcomes to face to face therapy. 

Members who completed at least 75% of the FearFighter journey achieved on average a 42% reduction in their generalised anxiety disorder (GAD-7) assessment score, compared to users who completed a lesser amount of the journey. In addition, members who completed at least 75% of the MoodCalmer program demonstrated a 24% reduction in their depression (PHQ-9) assessment scores, in comparison to other users who saw an average reduction of approximately 13%. 

"Magellan’s program delivers more than suggestions informed by cognitive therapy. The modules deliver the full, evidence-based CBT content, similar to therapy offered by a provider," notes NeuroFlow CEO and Co-Founder Chris Molaro. "We were excited to partner and provide the technology infrastructure in a clinically-based, engaging, and secure fashion to enhance Magellan’s proven programs. We are thrilled to see this come to fruition as evidenced by these impressive results."